Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

UT Health San Antonio Multispecialty and Research Hospital says it’s the first in Texas to add a new non-opioid medication to ...

Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

No use of the drug has received FDA approval as it can result in serious harm or death, Makary clarified. He emphasized the public must address the trend before it becomes the latest example of ...

Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level pain relief with fewer side effects, positioning it as a potential new standard of care. Eli Lilly's acquisition of ...

The FDA has updated COVID-19 vaccine regulations. Only people aged 65 and up, along with certain groups, will be eligible to receive booster shots. FDA officials are asking for more data around ...

The FDA will stop annual COVID vaccines for many people under age 65 this fall. Eligibility will be tied to specific medical conditions like asthma, HIV and pregnancy. Vaccines remain free for ...

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which blocks the NaV1.8 sodium channel to treat pain.

The big bet here is Journavx, a non-opioid acute pain treatment poised for FDA approval by early 2025. Analysts are optimistic, banking on strong demand and Medicare’s NOPAIN Act, which practically ...

LOUISVILLE, Ky. (WAVE) - The FDA is advising customers not to eat, sell or serve products from Pan-African Food Distributors Inc. The FDA says they found an active rodent infestation, with numerous ...

Vertex’s Journavx is the product of the pharma company’s internal NaV1.8 research. This twice-daily pill was awarded FDA approval in January as a treatment for moderate-to-severe acute pain in ...

The Langhorne, Pa., biopharmaceutical company said Tuesday it received a refusal-to-file letter from the FDA for the biologics license application for Molbreevi as a therapy to treat patients with ...